Revealing targeted therapy for human cancer by gene module maps
- PMID: 18199530
- DOI: 10.1158/0008-5472.CAN-07-0382
Revealing targeted therapy for human cancer by gene module maps
Abstract
A major goal of cancer research is to match specific therapies to molecular targets in cancer. Genome-scale expression profiling has identified new subtypes of cancer based on consistent patterns of variation in gene expression, leading to improved prognostic predictions. However, how these new genetic subtypes of cancers should be treated is unknown. Here, we show that a gene module map can guide the prospective identification of targeted therapies for genetic subtypes of cancer. By visualizing genome-scale gene expression in cancer as combinations of activated and deactivated functional modules, gene module maps can reveal specific functional pathways associated with each subtype that might be susceptible to targeted therapies. We show that in human breast cancers, activation of a poor-prognosis "wound signature" is strongly associated with induction of both a mitochondria gene module and a proteasome gene module. We found that 3-bromopyruvic acid, which inhibits glycolysis, selectively killed breast cells expressing the mitochondria and wound signatures. In addition, inhibition of proteasome activity by bortezomib, a drug approved for human use in multiple myeloma, abrogated wound signature expression and selectively killed breast cells expressing the wound signature. Thus, gene module maps may enable rapid translation of complex genomic signatures in human disease to targeted therapeutic strategies.
Similar articles
-
Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.Genome Biol. 2015 Apr 2;16(1):61. doi: 10.1186/s13059-015-0630-4. Genome Biol. 2015. PMID: 25886003 Free PMC article.
-
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S23-7. J Natl Compr Canc Netw. 2004. PMID: 19795532
-
Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.Cancer Res. 2007 Sep 1;67(17):8065-80. doi: 10.1158/0008-5472.CAN-07-1515. Cancer Res. 2007. PMID: 17804718
-
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.Cancer. 2005 Nov 1;104(9):1794-807. doi: 10.1002/cncr.21414. Cancer. 2005. PMID: 16178003 Review.
-
Discovery, Development, and clinical applications of bortezomib.Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):4-13. Oncology (Williston Park). 2004. PMID: 15688597 Review.
Cited by
-
Nuclear Respiratory Factor-1, a Novel SMAD4 Binding Protein, Represses TGF-β/SMAD4 Signaling by Functioning as a Transcriptional Cofactor.Int J Mol Sci. 2021 May 25;22(11):5595. doi: 10.3390/ijms22115595. Int J Mol Sci. 2021. PMID: 34070531 Free PMC article.
-
Algorithms for effective querying of compound graph-based pathway databases.BMC Bioinformatics. 2009 Nov 16;10:376. doi: 10.1186/1471-2105-10-376. BMC Bioinformatics. 2009. PMID: 19917102 Free PMC article.
-
Estrogenic control of mitochondrial function and biogenesis.J Cell Biochem. 2008 Dec 15;105(6):1342-51. doi: 10.1002/jcb.21936. J Cell Biochem. 2008. PMID: 18846505 Free PMC article. Review.
-
Temporal dynamics of protein complex formation and dissociation during human cytomegalovirus infection.Nat Commun. 2020 Feb 10;11(1):806. doi: 10.1038/s41467-020-14586-5. Nat Commun. 2020. PMID: 32041945 Free PMC article.
-
Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability.Cells. 2020 Sep 11;9(9):2077. doi: 10.3390/cells9092077. Cells. 2020. PMID: 32932819 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases